A Novel Pyrrole Acylsulfonamide, Compound <b>42</b> , as a Dual URAT1/GLUT9 Inhibitor: Potent Urate-Lowering Efficacy, Reduced Off-Target Effects, and Promising Druggability for Hyperuricemia
reduced serum uric acid and protected renal function without acute and subacute toxicity at high doses, supporting its promise as a candidate for hyperuricemia and gout.
Authors
- Zhenqian Wang (ORCID: https://orcid.org/0000-0002-1743-2227)
- Xinyong Liu (ORCID: https://orcid.org/0000-0002-7302-2214)
- Zitao Guo (ORCID: https://orcid.org/0000-0003-3852-2990)
- Peng Zhan (ORCID: https://orcid.org/0000-0002-9675-6026)
- Mingyu Yang (ORCID: https://orcid.org/0000-0003-0986-3825)
- Yuexin Xu
- Qian Yang
- Fan Yi
- Ting Wu
- Jianxin Pang (ORCID: https://orcid.org/0000-0002-0053-2723)
- Zhenkun Wu
- Xiaoyu Shi
Institutions
- Shandong University of Traditional Chinese Medicine (CN)
- Shandong University (CN)
- Peking University (CN)
- Tianjin Institute of Pharmaceutical Research (China) (CN)
- Southern Medical University (CN)
Publication Details
- Journal
- Journal of Medicinal Chemistry
- Published
- 2026-04-17
- DOI
- https://doi.org/10.1021/acs.jmedchem.6c00005
- Primary Topic
- Gout, Hyperuricemia, Uric Acid
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China